Reuters -- Novartis is confident its generic copy of Sanofi-Aventis’s blockbuster anti-clotting drug Lovenox will gain U.S. approval, the head of its generics unit said on Tuesday, but gave no indication as to timings.
Reuters -- Novartis is confident its generic copy of Sanofi-Aventis’s blockbuster anti-clotting drug Lovenox will gain U.S. approval, the head of its generics unit said on Tuesday, but gave no indication as to timings.
